BeOne Medicines annual debt-to-assets ratio
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Debt-to-Assets Ratio Growth & History (ONC)
BeOne Medicines's debt-to-assets ratio was 0.13 for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.13 | −0.19 | −58.75% |
| 2024 | 2024-12-31 | 0.33 | 0.17 | +103.58% |
| 2023 | 2023-12-31 | 0.16 | 0.07 | +71.31% |
| 2022 | 2022-12-31 | 0.09 | 0.01 | +14.93% |
| 2021 | 2021-12-31 | 0.08 | −0.08 | −49.18% |
| 2020 | 2020-12-31 | 0.16 | 0.09 | +115.25% |
| 2019 | 2019-12-31 | 0.07 | 0.05 | +238.06% |
| 2018 | 2018-12-31 | 0.02 | 0.00 | +24.87% |
| 2017 | 2017-12-31 | 0.02 | −0.02 | −58.62% |
| 2016 | 2016-12-31 | 0.04 | — | — |
BeOne Medicines quarterly debt-to-assets ratio
Q4.16
Q1.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.13 | −0.03 | −18.73% |
| Q1 2026 | 2026-03-31 | 0.14 | −0.04 | −20.65% |
| Q4 2025 | 2025-12-31 | 0.13 | −0.19 | −58.75% |
| Q3 2025 | 2025-09-30 | 0.12 | −0.07 | −38.94% |
| Q2 2025 | 2025-06-30 | 0.16 | −0.03 | −14.66% |
| Q1 2025 | 2025-03-31 | 0.17 | −0.02 | −9.03% |
| Q4 2024 | 2024-12-31 | 0.33 | 0.17 | +103.58% |
| Q3 2024 | 2024-09-30 | 0.19 | 0.08 | +80.02% |
| Q2 2024 | 2024-06-30 | 0.19 | 0.07 | +61.28% |
| Q1 2024 | 2024-03-31 | 0.19 | 0.10 | +104.94% |
| Q4 2023 | 2023-12-31 | 0.16 | 0.07 | +71.31% |
| Q3 2023 | 2023-09-30 | 0.10 | −0.00 | −0.67% |
| Q2 2023 | 2023-06-30 | 0.12 | 0.03 | +37.99% |
| Q1 2023 | 2023-03-31 | 0.09 | 0.01 | +9.27% |
| Q4 2022 | 2022-12-31 | 0.09 | 0.01 | +14.93% |
| Q3 2022 | 2022-09-30 | 0.11 | −0.03 | −20.16% |
| Q2 2022 | 2022-06-30 | 0.09 | −0.04 | −30.38% |
| Q1 2022 | 2022-03-31 | 0.08 | −0.03 | −23.65% |
| Q4 2021 | 2021-12-31 | 0.08 | −0.08 | −49.18% |
| Q3 2021 | 2021-09-30 | 0.13 | 0.09 | +202.21% |
| Q2 2021 | 2021-06-30 | 0.12 | 0.07 | +138.46% |
| Q1 2021 | 2021-03-31 | 0.11 | 0.08 | +216.97% |
| Q4 2020 | 2020-12-31 | 0.16 | 0.09 | +115.25% |
| Q3 2020 | 2020-09-30 | 0.04 | −0.03 | −38.74% |
| Q2 2020 | 2020-06-30 | 0.05 | −0.00 | −8.26% |
| Q1 2020 | 2020-03-31 | 0.03 | −0.02 | −34.86% |
| Q4 2019 | 2019-12-31 | 0.07 | 0.05 | +238.06% |
| Q3 2019 | 2019-09-30 | 0.07 | 0.05 | +247.37% |
| Q2 2019 | 2019-06-30 | 0.06 | 0.02 | +53.81% |
| Q1 2019 | 2019-03-31 | 0.05 | 0.04 | +374.64% |
| Q4 2018 | 2018-12-31 | 0.02 | 0.00 | +24.87% |
| Q3 2018 | 2018-09-30 | 0.02 | 0.01 | +139.36% |
| Q2 2018 | 2018-06-30 | 0.04 | — | — |
| Q1 2018 | 2018-03-31 | 0.01 | 0.00 | +70.74% |
| Q4 2017 | 2017-12-31 | 0.02 | −0.02 | −58.62% |
| Q3 2017 | 2017-09-30 | 0.01 | — | — |
| Q1 2017 | 2017-03-31 | 0.01 | — | — |
| Q4 2016 | 2016-12-31 | 0.04 | — | — |
BeOne Medicines debt-to-assets ratio trends
Over the last five fiscal years, BeOne Medicines's debt-to-assets ratio decreased from 0.16 to 0.13, a change of −0.03. The latest reported quarter, Q2 2026, shows 0.13.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
